ARCT - Arcturus Therapeutics Holdings Inc.
NASDAQ
->
Healthcare
->
Biotechnology
San Diego,
United States
Type: Equity
ARCT price evolution
ARCT
| (in millions $) | 30 Jun 2024 | 1 May 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $315.33 | $343.4 | $347 | $346.92 |
| Short term investments | ||||
| Net receivables | $24.09 | $27.06 | $32.06 | $38.22 |
| Inventory | ||||
| Total current assets | $347.01 | $375.79 | $386.59 | $393.27 |
| Long term investments | $1.89 | $1.89 | $1.89 | $22.13 |
| Property, plant & equipment | $39.72 | $41.18 | $40.93 | $42.25 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $41.6 | $43.06 | $42.81 | $64.38 |
| Total investments | $1.89 | $1.89 | $1.89 | $22.13 |
| Total assets | $388.61 | $418.85 | $429.4 | $457.65 |
| Current liabilities | ||||
| Accounts payable | $13.9 | $9.14 | $5.28 | $18.36 |
| Deferred revenue | $53.71 | $83.31 | $87.33 | $82.68 |
| Short long term debt | ||||
| Total current liabilities | $91.72 | $115.43 | $81.99 | $87.68 |
| Long term debt | $26.96 | $27.65 | $25.91 | $47.02 |
| Total noncurrent liabilities | $38.31 | $39.45 | $68.9 | $89.91 |
| Total debt | $26.96 | $27.65 | $25.91 | $47.02 |
| Total liabilities | $130.03 | $154.88 | $150.89 | $177.59 |
| Shareholders' equity | ||||
| Retained earnings | -$411.9 | -$394.68 | -$367.87 | -$356.16 |
| Other shareholder equity | ||||
| Total shareholder equity | $258.58 | $263.97 | $278.51 | $280.06 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $347 | $391.88 | $370.49 | $462.89 |
| Short term investments | ||||
| Net receivables | $32.06 | $2.76 | $3.37 | $2.13 |
| Inventory | ||||
| Total current assets | $386.59 | $403.33 | $378.96 | $467.79 |
| Long term investments | $1.89 | $2.09 | $2.59 | $0.11 |
| Property, plant & equipment | $40.93 | $44.96 | $11.26 | $8.56 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $42.81 | $47.05 | $13.85 | $8.67 |
| Total investments | $1.89 | $2.09 | $2.59 | $0.11 |
| Total assets | $429.4 | $450.39 | $392.81 | $476.46 |
| Current liabilities | ||||
| Accounts payable | $5.28 | $7.45 | $10.06 | $10.77 |
| Deferred revenue | $87.33 | $48.72 | $63.41 | $30.62 |
| Short long term debt | $60.66 | $22.47 | ||
| Total current liabilities | $81.99 | $126.98 | $99.54 | $49.52 |
| Long term debt | $25.91 | $30.22 | $45.13 | $17.87 |
| Total noncurrent liabilities | $68.9 | $53.09 | $65.07 | $30.38 |
| Total debt | $25.91 | $90.87 | $67.61 | $17.87 |
| Total liabilities | $150.89 | $180.07 | $164.6 | $79.9 |
| Shareholders' equity | ||||
| Retained earnings | -$367.87 | -$338.14 | -$347.49 | -$143.82 |
| Other shareholder equity | ||||
| Total shareholder equity | $278.51 | $270.31 | $228.21 | $396.55 |
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $49.86 | $38.01 | $30.86 | $45.14 |
| Cost of revenue | ||||
| Gross Profit | $49.86 | $38.01 | $30.86 | $45.14 |
| Operating activities | ||||
| Research & development | $58.67 | $53.57 | $36.62 | $51.08 |
| Selling, general & administrative | $12.32 | $14.85 | $12.51 | $13.38 |
| Total operating expenses | $70.98 | $68.42 | $49.13 | $64.45 |
| Operating income | -$21.13 | -$30.41 | -$18.27 | -$19.31 |
| Income from continuing operations | ||||
| EBIT | -$17.37 | -$26.45 | -$18.33 | -$19.31 |
| Income tax expense | -$0.15 | $0.37 | $0.26 | $0.89 |
| Interest expense | -$6.88 | -$3.98 | ||
| Net income | ||||
| Net income | -$17.22 | -$26.82 | -$11.71 | -$16.22 |
| Income (for common shares) | -$17.22 | -$26.82 | -$11.71 | -$16.22 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $166.8 | $206 | $12.36 | $9.54 |
| Cost of revenue | ||||
| Gross Profit | $166.8 | $206 | $12.36 | $9.54 |
| Operating activities | ||||
| Research & development | $192.13 | $147.75 | $173.76 | $57.85 |
| Selling, general & administrative | $52.87 | $46.07 | $41.45 | $23.22 |
| Total operating expenses | $245 | $193.82 | $215.21 | $81.06 |
| Operating income | -$78.2 | $12.18 | -$202.85 | -$71.52 |
| Income from continuing operations | ||||
| EBIT | -$44.48 | $11.06 | -$201.75 | -$71.79 |
| Income tax expense | $1.83 | $1.29 | ||
| Interest expense | -$16.59 | $0.42 | $1.92 | $0.36 |
| Net income | ||||
| Net income | -$29.73 | $9.35 | -$203.67 | -$72.15 |
| Income (for common shares) | -$29.73 | $9.35 | -$203.67 | -$72.15 |
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Net income | -$17.22 | -$26.82 | -$11.71 | -$16.22 |
| Operating activities | ||||
| Depreciation | $0.91 | $0.9 | $0.81 | $0.83 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $9.42 | $10.09 | $8.81 | $9.27 |
| Total cash flows from operations | -$30.14 | -$5.56 | -$0.63 | -$32.41 |
| Investing activities | ||||
| Capital expenditures | -$0.33 | -$0.24 | -$0.88 | -$0.98 |
| Investments | ||||
| Total cash flows from investing | -$0.33 | -$0.24 | -$0.88 | -$0.98 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $2.4 | $2.19 | $1.34 | $1.84 |
| Net borrowings | -$20 | $20 | ||
| Total cash flows from financing | $2.4 | $2.19 | -$18.66 | $21.84 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$28.07 | -$3.61 | -$20.16 | -$11.55 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$29.73 | $9.35 | -$203.67 | -$72.15 |
| Operating activities | ||||
| Depreciation | $2.96 | $1.53 | $1.19 | $0.88 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $34.65 | $30.61 | $28.91 | $6.76 |
| Total cash flows from operations | -$18.1 | $31.99 | -$135.04 | -$42.86 |
| Investing activities | ||||
| Capital expenditures | -$2.9 | -$7.73 | -$3.41 | -$1.74 |
| Investments | ||||
| Total cash flows from investing | -$2.9 | -$7.73 | -$3.41 | -$1.74 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $3.28 | $2.14 | $1.42 | $436.14 |
| Net borrowings | -$27.36 | -$5 | $46.6 | |
| Total cash flows from financing | -$24.09 | -$2.86 | $48.02 | $436.14 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$45.09 | $21.41 | -$90.43 | $391.54 |
News
Fundamentals
| Market cap | $461.61M |
|---|---|
| Enterprise value | $173.24M |
| Shares outstanding | 27.04M |
| Revenue | $163.87M |
|---|---|
| EBITDA | -$78.00M |
| EBIT | -$81.45M |
| Net Income | -$71.96M |
| Revenue Q/Q | 373.99% |
| Revenue Y/Y | -38.04% |
| P/E ratio | -6.41 |
|---|---|
| EV/Sales | 1.06 |
| EV/EBITDA | -2.22 |
| EV/EBIT | -2.13 |
| P/S ratio | 2.82 |
| P/B ratio | 1.79 |
| Book/Share | 9.56 |
| Cash/Share | 11.66 |
| EPS | -$2.66 |
|---|---|
| ROA | -16.99% |
| ROE | -26.62% |
| Debt/Equity | 0.54 |
|---|---|
| Net debt/EBITDA | 2.38 |
| Current ratio | 3.78 |
| Quick ratio | 3.78 |